JAK3 tyrosine kinase inhibitors (Aventis)

N/A

Report date: 2025/03/20 20:00:06

NME

Base Information

Drug NameJAK3 tyrosine kinase inhibitors (Aventis)

Drug Alias NameJanus kinase 3 inhibitors (Aventis)Janus kinase 3 inhibitors (sanofi-aventis)JAK3 tyrosine kinase inhibitors (sanofi-aventis)

ClassificationSmall molecules > Heterocyclic drugs

Mechanisms of ActionTyrosine-protein kinase JAK3 inhibitors

TargetsTyrosine-protein kinase JAK3

Therapy Area/IndicationsInflammation

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryFrance

CombinationsNo

Global Highest StatusPending (Preclinical)

Highest Status in ChinaN/A

Originator CompaniesAventis

China Registration ClassN/A

Active CompaniesN/A

Inactive CompaniesSanofi Aventis

Active IndicationsN/A

Inactive IndicationsInflammation

ATC CodeN/A